Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Biochim Biophys Acta. 2013 Mar 5;1833(6):1489–1497. doi: 10.1016/j.bbamcr.2013.02.026

Figure 1. DDX3 protects MCF-7 cells from DNA damage-induced apoptosis but potentiates it in HeLa cells.

Figure 1

Figure 1

Wild-type (WT) and DDX3 knockdown (KD) stable MCF-7 cells were treated for the indicated times with (A) 1 μM staurosporine, (B) 1 μM thapsigargin (after overnight preincubation in serum free media), or (C) 10 μM camptothecin (after overnight preincubation in serum free media). (D) HeLa cells and (E) MDA-MB-231 cells were treated with 10 μM camptothecin for the indicated time points (after overnight preincubation in serum free media). Cell extracts were collected and immunoblotted for active caspase-3/7, cleaved PARP, DDX3, and β-actin as a loading control. (F) MCF-7, (G) HeLa and (H) MDA-MB231 wild-type (WT) and DDX3 knockdown (KD) cells were treated with 10 μM Adriamycin for the indicated time points, followed by immunoblotting for active caspase-3/7, cleaved-PARP, DDX3 and β-actin. Experiments were repeated at least two times with similar results.